Gabapentin (All indications)

Cognitive developmental disorders/delay (3-6 years old)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10095
R48902		 Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Diagnosis Mental retardation (F70–F79) (mean age of 3.7 years old) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 0.25 [0.01;4.15] C
excluded (control group) 		0/378   15/2,916 15 378
ref
S8517
R48903		 Coste (Controls unexposed, NOS) (Mixed indications), 2020 Diagnosis Mental retardation (F70–F79) (mean age of 3.6 years old) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 0.67 [0.04;10.66] C 0/378   3,398/1,710,441 3,398 378
ref
Total 1 studies 0.67 [0.04;10.66] 3,398 378
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Controls unexposed, NOS) (Mixed indications), 2020Coste, 2020 1 0.67[0.04; 10.66]3,3983780%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, NOS) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.67[0.04; 10.66]3,398378 -NACoste (Controls unexposed, NOS) (Mixed indications), 2020 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.67[0.04; 10.66]3,398378 -NACoste (Controls unexposed, NOS) (Mixed indications), 2020 1 Tags Adjustment   - No  - No 0.67[0.04; 10.66]3,398378 -NACoste (Controls unexposed, NOS) (Mixed indications), 2020 1 All studiesAll studies 0.67[0.04; 10.66]3,398378 -NACoste (Controls unexposed, NOS) (Mixed indications), 2020 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10095

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.67[0.04; 10.66]3,398378 -NACoste (Controls unexposed, NOS) (Mixed indications), 2020 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.25[0.01; 4.15]15378 -NACoste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 10.510.01.0